The young breast cancer patient therapy – new opportunities, new challenges Case report

Article Sidebar

PDF


Published: Jun 30, 2019
DOI: https://doi.org/10.24292/01.OR.219090519
Keywords:
breast cancer in young patient, non-pegylated liposomal doxorubicin, ribociclib, metastatic disease

Main Article Content

Joanna Załuska-Kusz
Department of Chemotherapy, Greater Poland Cancer Center
Joanna Kufel-Grabowska
1. Department of Chemotherapy, Greater Poland Cancer Center. 2. Department of Electroradiology, Poznan University of Medical Sciences

Abstract

The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.


 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Załuska-Kusz J, Kufel-Grabowska J. The young breast cancer patient therapy – new opportunities, new challenges. OncoReview [Internet]. 2019Jun.30 [cited 2024Nov.22];9(2(34):45-0. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/412
Issue
Vol 9 No 2(34) (2019)
Section
CARDIO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxity and preserved antitumor efficacy of liposome encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-54.
2. Batist G, Harris L, Azarina N et al. Improved anti-tumor response rate with decreased cardiotoxity of non pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who haved received prior adjuvant doxorubicin: results of a retrospective analysys. Anticancer Drugs 2006; 17: 587-95.
3. Meiyuan X, Feifei Y, Sufen Y, Peng S. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized trials. PloS One 2015; 10(7): e0133569.